Jump to content

25F-NBOMe

From Wikipedia, the free encyclopedia

25F-NBOMe
Clinical data
Other names2C-F-NBOMe; NBOMe-2C-F; N-(2-Methoxybenzyl)-4-fluoro-2,5-dimethoxyphenethylamine
Drug classSerotonin 5-HT2 receptor agonist; Possible serotonergic psychedelic; Possible hallucinogen
ATC code
  • None
Identifiers
  • 2-(4-fluoro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
PubChem CID
Chemical and physical data
FormulaC18H22FNO3
Molar mass319.376 g·mol−1
3D model (JSmol)
  • COC1=CC=CC=C1CNCCC2=CC(=C(C=C2OC)F)OC
  • InChI=1S/C18H22FNO3/c1-21-16-7-5-4-6-14(16)12-20-9-8-13-10-18(23-3)15(19)11-17(13)22-2/h4-7,10-11,20H,8-9,12H2,1-3H3
  • Key:DFTJMIFNIHIWAJ-UHFFFAOYSA-N

25F-NBOMe, also known as 2C-F-NBOMe or NBOMe-2C-F as well as N-(2-methoxybenzyl)-4-fluoro-2,5-dimethoxyphenethylamine, is a serotonin 5-HT2 receptor agonist and possible serotonergic psychedelic of the phenethylamine, 2C, and 25-NB (NBOMe) families.[1][2] It is the NBOMe (N-(2-methoxybenzyl)) derivative of 2C-F.[1][2] The drug acts as a potent agonist of the serotonin 5-HT2A and 5-HT2C receptors and also shows interactions with certain other targets, such as the serotonin 5-HT2B receptor.[1][2] However, it shows more than an order of magnitude lower potency as a serotonin 5-HT2A receptor agonist than certain other NBOMe drugs like 25I-NBOMe and 25B-NBOMe in vitro.[2] 25F-NBOMe was first described in the scientific literature by 2010.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d Hansen M (2010-12-16). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Ph.D. thesis). University of Copenhagen. doi:10.13140/RG.2.2.33671.14245.
  2. ^ a b c d Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, et al. (March 2014). "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience. 5 (3): 243–249. doi:10.1021/cn400216u. PMC 3963123. PMID 24397362.
[edit]